ライフサイエンスコーパス: ATP-citrate lyase

1 (via acetyl-CoA synthetase) or citrate (via ATP citrate lyase).

2 -like protein 3 and 4, apolipoprotein V, and ATP citrate lyase.

3 on a cytosolic enzyme of citrate metabolism, ATP citrate lyase.

4 inhibitors of the recombinant human form of ATP-citrate lyase.

5 een observed with mammalian, yeast, and mold ATP-citrate lyase.

6 lated genes, such as fatty acid synthase and ATP-citrate lyase.

7 s of the reductive tricarboxylic acid cycle, ATP citrate lyase, 2-oxoglutarate:ferredoxin oxidoreduct

8 Lowering ATP citrate lyase 88% did not inhibit glucose-induced in

9 n of these biosynthetic genes, which include ATP citrate lyase, ACC, FAS, and stearoyl-CoA desaturase

10 ATP citrate lyase (ACL) catalyzes an ATP-dependent biosy

11 The ATP citrate lyase (ACL) inhibitor, bempedoic acid, reduc

12 in BNIP-H/Caytaxin links kinesin-1 (KLC1) to ATP citrate lyase (ACL), a key enzyme for ACh synthesis,

13 ondria-derived citrate through the action of ATP citrate lyase (ACL).

14 ells is dependent on adenosine triphosphate (ATP)-citrate lyase (ACL), the enzyme that converts gluco

15 d has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase

16 ATP-citrate lyase (ACL) is an essential enzyme of the re

17 nt inhibitory activities (IC(50) s <5 uM) of ATP-citrate lyase (ACL), a new drug target for the treat

18 Here we showed that ATP-citrate lyase (ACL), an enzyme converting citrate to

19 zyme A (acetyl-CoA) production by the enzyme ATP-citrate lyase (ACL).

20 cose concentration, and nuclear functions of ATP-citrate lyase (ACL).

21 r to the amino and carboxy portions of human ATP-citrate lyase (ACL).

22 tly inherited variants in the genes encoding ATP citrate lyase (ACLY) and HMGCR to create instruments

23 The ATP citrate lyase (ACLY) enzyme cleaves cytosolic citrat

24 f acetate, which can be blocked by silencing ATP citrate lyase (ACLY) in CAFs.

25 We investigated the requirement for ATP citrate lyase (ACLY) in NK cell function using an in

26 ATP citrate lyase (ACLY) is the predominant nucleocytoso

27 ATP citrate lyase (ACLY) links substrate availability an

28 ATP citrate lyase (Acly) plays a pivotal role in chromat

29 Here, we show ATP citrate lyase (Acly) to be activated in inflammatory

30 ction stimulates the S455 phosphorylation of ATP citrate lyase (ACLY), a pivotal enzyme that links ci

31 report that the acetyl-CoA-producing enzyme, ATP citrate lyase (ACLY), is a key regulator of macropin

32 etyl-CoA derived from citrate via the enzyme ATP citrate lyase (ACLY).

33 nthase (FASN), acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY)].

34 l-CoA synthetase 2 (ACSS2) while maintaining ATP-citrate lyase (ACLY) activity.

35 cetate, which are processed to acetyl-CoA by ATP-citrate lyase (ACLY) and acyl-CoA synthetase short-c

36 pogenesis (DNL), is produced from citrate by ATP-citrate lyase (ACLY) and from acetate through AcCoA

37 eomics and metabolite profiling, we identify ATP-citrate lyase (ACLY) as a distinctly mTORC2-sensitiv

38 ytosolic acetyl CoA (Ac-CoA), is produced by ATP-citrate lyase (ACLY) from mitochondria-derived citra

39 y-3-methylglutaryl-CoA reductase (HMGCR) and ATP-citrate lyase (ACLY) in a TGF-beta receptor/PI3K/pro

40 ATP-citrate lyase (ACLY) is a central metabolic enzyme a

41 ATP-citrate lyase (ACLY) is a cytosolic enzyme that cata

42 ATP-citrate lyase (ACLY) is a major source of nucleocyto

43 Here, we show that ATP-citrate lyase (Acly) is enriched in vesicles and pro

44 ATP-citrate lyase (Acly) is one of two cytosolic enzymes

45 In this study, we report that nuclear ATP-citrate lyase (ACLY) is phosphorylated at S455 downs

46 ATP-citrate lyase (ACLY) is upregulated or activated in

47 Inhibition of hepatic ATP-citrate lyase (ACLY) is widely accepted as the main

48 ATP-citrate lyase (ACLY) links carbohydrate and lipid me

49 ATP-citrate lyase (ACLY) synthesizes cytosolic acetyl co

50 phosphate kinase-mediated phosphorylation of ATP-citrate lyase (ACLY) which enhances the ACLY activit

51 ATP-citrate lyase (ACLY), a key enzyme for lipid synthes

52 s dysregulation is mediated by activation of ATP-citrate lyase (ACLY), a key enzyme that generates ac

53 including citrate/isocitrate carrier (CIC), ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC) a

54 nding proteins in breast cancer, identifying ATP-citrate lyase (ACLY), an enzyme in the de novo lipog

55 Six2Cre-mediated removal of ATP-citrate lyase (Acly), an enzyme that converts citrat

56 tion leads to increased levels of endogenous ATP-citrate lyase (ACLY), and this is accompanied by inc

57 memory is controlled by the metabolic enzyme ATP-citrate lyase (ACLY), which produces acetyl coenzyme

58 ng an intracellular pool of acetyl CoA in an ATP-citrate lyase (ACLY)-dependent manner.

59 ndent on oxidative energy metabolism and the ATP-citrate lyase (ACLY).

60 cell lines deficient in these mitochondrial [ATP-citrate lyase (ACLY)]-, cytosolic [acetyl-CoA synthe

61 carboxylase (ACCalpha), and increased FASN, ATP citrate lyase(ACLY), and malic enzyme (ME) protein e

62 c acidosis is associated with an increase in ATP citrate lyase activity and protein abundance, and is

63 hypocitraturia and increased renal cortical ATP citrate lyase activity by 28%.

64 raturia in rats and increased renal cortical ATP citrate lyase activity by 67% after 7 d.

65 ali feeding was associated with no change in ATP citrate lyase activity.

66 ults showed that nucleocytosolic citrate and ATP-citrate lyase activity drove IL1B, IL10, and IL23A e

67 a manner involving fatty acid oxidation and ATP-citrate lyase activity.

68 Thus, human ATP:citrate lyase activity is regulated in vitro alloste

69 r weight loss, is a competitive inhibitor of ATP-citrate lyase, an extramitochondrial enzyme involved

70 l-length HCV RNAs express elevated levels of ATP citrate lyase and acetyl-CoA synthetase genes, both

71 and elongation in tumour cells by targeting ATP citrate lyase and fatty acid elongase 6, as well as

72 cumulation of citrate and the stimulation of ATP citrate lyase and fatty-acid synthase leading to de

73 expression by RNAi inhibits up-regulation of ATP citrate lyase and fatty-acid synthase.

74 fically deubiquitinates and thus upregulates ATP citrate lyase and oxoglutarate dehydrogenase, two ke

75 dehydrogenase phosphatase, while repressing ATP citrate lyase and short-chain acyl-CoA synthetase ge

76 , in both cases, lower levels of acetyl-CoA, ATP-citrate lyase and mitochondrial membrane potential w

77 rom its catalytic histidine to histidines on ATP-citrate lyase and succinic thiokinase.

78 been completed for bempedoic acid (targeting ATP-citrate lyase) and inclisiran (an interference RNA-b

79 fatty-acid synthase, acetyl-CoA carboxylase, ATP citrate lyase, and Glut-1 were significantly increas

80 m proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.

81 Induction of spot 14, ATP citrate-lyase, and fatty acid synthase polypeptides,

82 is identified an important metabolic enzyme, ATP-citrate lyase, as a novel PTPN2 substrate.

83 The rates of phosphorylation of ATP-citrate lyase by nm23-H1(S120G) and nm23-H1(P96S) we

84 ynthesis of fatty acids from glucose include ATP-citrate lyase (CL) and fatty acid synthase (FAS).

85 Flux through ATP-citrate lyase, combined with malic enzyme activity,

86 nes encoding the alpha- and beta-subunits of ATP citrate lyase could be amplified from both organisms

87 concept directly, we used acetate-dependent, ATP citrate lyase-deficient mouse embryonic fibroblasts

88 the situation observed for other prokaryotic ATP-citrate lyase enzymes, the C. tepidum enzyme was not

89 ratio of ATP/ADP, phospholipid content, and ATP citrate lyase expression.

90 eam of FAS, acetyl-CoA carboxylase-alpha and ATP-citrate lyase, fails to activate caspase-8 or to eli

91 RNAs coding for key lipogenic (malic enzyme, ATP citrate-lyase, fatty acid synthase), glycolytic (pyr

92 ed induction of mRNAs encoding malic enzyme, ATP citrate-lyase, fatty acid synthase, liver-type pyruv

93 Both forms of RuBisCO, together with ATP citrate lyase genes in the rTCA cycle, increase with

94 enic genes, including SCD1, FAS, ACC1, ACC2, ATP-citrate lyase, glycerol kinase, and HMG-CoA reductas

95 the hypothesis that compounds which inhibit ATP-citrate lyase have the potential to be a novel class

96 These results suggest an important role for ATP citrate lyase in proximal tubular citrate metabolism

97 ved pyruvate through the citrate shuttle and ATP citrate lyase in the cytosol.

98 nase and fumarase and activate the cytosolic ATP-citrate lyase in vivo, acting as a direct regulator

99 citrate transporter Slc25A1, and the nuclear ATP-citrate lyase, in association with intracellular acc

100 gnificant differences from other prokaryotic ATP-citrate lyases, including the enzyme from the closel

101 with the CRM hydroxycitrate, an inhibitor of ATP citrate lyase, induced the depletion of regulatory T

102 Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipopro

103 create instruments that mimic the effect of ATP citrate lyase inhibitors and HMGCR inhibitors (stati

104 Genetic variants that mimic the effect of ATP citrate lyase inhibitors and statins appeared to low

105 ATP citrate lyase is an enzyme in the cholesterol-biosyn

106 Whether the genetic inhibition of ATP citrate lyase is associated with deleterious outcome

107 ATP-citrate lyase is an epigenetic regulator to promote

108 Interestingly, the expression of ATP-citrate lyase is increased in Nat8l-silenced adipocy

109 Fatty acid synthase (FASN) and ATP-citrate lyase, key enzymes of de novo lipogenesis, a

110 ntiation, both processes being attenuated by ATP-citrate lyase knockdown.

111 igh-fat diet (HFD) results in suppression of ATP citrate-lyase levels in tissues such as adipose and

112 cific gene loci via citrate accumulation and ATP-citrate lyase-mediated generation of acetyl CoA.

113 Neither lifelong genetic inhibition of ATP citrate lyase nor lifelong genetic inhibition of HMG

114 Phosphorylation of C. tepidum ATP-citrate lyase occurred, presumably on a histidine re

115 Manipulating the expression of ATP citrate lyase or the canonical TCA-cycle enzyme acon

116 atty acid synthase (FAS), and phosphorylated ATP-citrate lyase (pACL).

117 ATP citrate-lyase produces acetyl-CoA in the nucleus and

118 Renal cortical ATP citrate lyase protein abundance increased by 29% aft

119 e shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipopro

120 ties, the catalytic properties of C. tepidum ATP-citrate lyase showed marked similarities to the euka

121 include FA synthase, acetyl-CoA carboxylase, ATP citrate lyase, stearoyl-CoA desaturase 1, cluster of

122 studies we show that the levels of mRNA for ATP citrate lyase, the enzyme that produces acetyl-CoA,

123 Bempedoic acid inhibits ATP citrate lyase, the enzyme upstream of HMG-CoA reduct

124 exported to the cytoplasm is metabolized by ATP citrate lyase, ultimately regenerating mitochondrial

125 Recombinantly expressed human ATP:citrate lyase was purified from E. coli, and its kin

126 One of the key enzymes, ATP-citrate lyase, was purified to apparent homogeneity

127 mitochondrial citrate/malate antiporter and ATP citrate lyase, which converts cytosolic citrate into

128 Activity and protein of ATP citrate lyase, which uses anaplerotic products in th

129 ins MyD88 and TRIF resulted in activation of ATP-citrate lyase, which in turn facilitated the inducti

130 Two cytosol ATP-citrate lyases, which take part in the cycle of citr

131 Inhibition of ATP citrate lyase with the competitive inhibitor, 4S-hyd